CLL-IPI Score Calculator
Use this tool to estimate a Chronic Lymphocytic Leukemia International Prognostic Index (CLL-IPI) score from standard clinical and biologic factors.
Educational use only. This does not replace oncology evaluation, treatment planning, or personalized risk counseling.
What is the CLL-IPI?
The CLL-IPI (Chronic Lymphocytic Leukemia International Prognostic Index) is a risk stratification model used in CLL to estimate prognosis at diagnosis or early in the disease course. It combines age, clinical stage, and key lab/genetic markers into a single score.
Clinicians use this kind of index to support conversations about expected disease behavior and follow-up intensity. It is not a stand-alone treatment decision engine, but it can be very useful when interpreted with clinical judgment.
Scoring factors used in this calculator
| Factor | Condition | Points |
|---|---|---|
| TP53 status | del(17p) and/or TP53 mutation | 4 |
| IGHV mutation status | Unmutated IGHV | 2 |
| β2-microglobulin | > 3.5 mg/L | 2 |
| Clinical stage | Rai I-IV (or Binet B/C) | 1 |
| Age | > 65 years | 1 |
How to interpret the score
- 0-1 points: Low risk (historically favorable outcomes)
- 2-3 points: Intermediate risk
- 4-6 points: High risk
- 7-10 points: Very high risk
In the original CLL-IPI publication cohorts, the risk groups were associated with different 5-year overall survival estimates. Modern therapies can change outcomes substantially, so always contextualize these numbers with current treatment options.
Practical notes for patients and clinicians
1) Timing matters
Risk markers may be assessed at diagnosis and sometimes repeated later. Clonal evolution can occur, especially before treatment changes.
2) Lab quality matters
Results for TP53 mutation testing, FISH for del(17p), and IGHV mutation status should come from validated laboratories with CLL expertise.
3) Risk is only part of management
Symptoms, cytopenias, bulky disease, patient comorbidity, preferences, and treatment access are central to real-world decisions. A score should support discussion, not replace it.
Example scoring walkthrough
A 70-year-old patient with Rai II stage, β2-microglobulin 4.1 mg/L, unmutated IGHV, and no TP53 aberration would score:
- Age > 65: +1
- Advanced clinical stage: +1
- β2-microglobulin > 3.5: +2
- Unmutated IGHV: +2
- No TP53 aberration: +0
Total = 6 points, corresponding to the high-risk category.
Frequently asked questions
Is this calculator for diagnosis?
No. CLL-IPI is a prognostic model for people already evaluated for CLL. It does not diagnose leukemia.
Can I use this to choose a specific drug?
Not by itself. Treatment selection depends on many factors beyond CLL-IPI, including current guideline recommendations and patient-specific clinical details.
What if one variable is unknown?
You should avoid calculating partial scores for clinical decision-making. Complete data improves reliability.
Bottom line
The CLL-IPI remains a practical framework for discussing prognosis in chronic lymphocytic leukemia. Use the calculator above for fast estimation, then combine the result with full clinical assessment and contemporary oncology guidance.